Physician profile
Aaron B Davis
NPI 1417519679
$2,507.29
in general payments reported to CMS, 2019-2025
23 companies · $33.12 in 2025
The $33.12 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $828 · 2023: $1,115 · 2024: $353 · 2025: $33.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496 · Education: $4.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.82 |
| Education | $4.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $682.28 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $286.17 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Indivior INC. | $259.32 | 2021-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $177.30 | 2021-2023 | Invega Trinza, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $162.24 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.96 | 2021-2024 | Trintellix |
| Corium, LLC | $121.95 | 2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.16 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $95.17 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $77.40 | 2022-2023 | Austedo Xr, Austedo |
| Ironshore Pharmaceuticals INC. | $66.43 | 2023-2024 | Jornay Pm |
| Alkermes, INC. | $61.27 | 2023-2025 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $51.47 | 2022-2023 | Quviviq |
| Neurocrine Biosciences, INC. | $49.30 | 2023 | Ingrezza |
| Lundbeck LLC | $36.38 | 2023-2024 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $26.61 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.97 | 2022 | |
| Braeburn INC. | $17.68 | 2024 | Brixadi |
| Biohaven Pharmaceutical Holding Company LTD. | $15.52 | 2022 | |
| Merck Sharp & Dohme LLC | $15.41 | 2023 | Belsomra |
| Novo Nordisk INC | $15.33 | 2022 | |
| Exact Sciences Corporation | $14.95 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $14.02 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.